Combination of anti TIM-3 antibody MBG453 and anti TGF-beta antibody NIS793, with or without decitabine or the anti PD-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome

Combination therapies comprising TIM-3 inhibitors and TGF-β inhibitors are disclosed. The combinations can be used to treat or prevent cancerous conditions and disorders, including myelofibrosis or myelodysplastic syndrome.

Saved in:
Bibliographic Details
Main Authors SUN, Haiying, MARATHE, Anshu, KHANSHAN, Fariba, DOSTALEK, Mirek, FABRE, Claire, RINNE, Mikael, VANASSE, K. Gary J, MANENTI, Luigi
Format Patent
LanguageEnglish
Published 30.06.2022
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Combination therapies comprising TIM-3 inhibitors and TGF-β inhibitors are disclosed. The combinations can be used to treat or prevent cancerous conditions and disorders, including myelofibrosis or myelodysplastic syndrome.
Bibliography:Application Number: AU20200410266